References
- Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M. (2001a). Passionflower in the treatment of opiates withdrawal: A double-blind randomized controlled trial. J Clin Pharm Ther, 26, 369–373.
- Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. (2001b). Passion flower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther, 26, 363–367.
- Benowitz NL. (1996). Pharmacology of nicotine: Addiction and therapeutics. Annu Rev Pharmacol Toxicol, 36, 597–613.
- Dani JA, De Biasi M. (2001). Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav, 70, 439–446.
- Dhawan K, Kumar S, Sharma A. (2002). Nicotine reversal effects of the benzoflavone moiety from Passiflora incarnata Linneaus in mice. Addict Biol, 7, 435–441.
- Dhawan K. (2003). Drug/substance reversal effects of a novel tri-substituted benzoflavone moiety (BZF) isolated from Passiflora incarnata Linn.–a brief perspective. Addict Biol, 8, 379–386.
- DiFranza JR, Wellman RJ. (2007). Sensitization to nicotine: How the animal literature might inform future human research. Nicotine Tob Res, 9, 9–20.
- Fiore M, Jaen CR, Baker TB. Bailey WC, Benett G. (2008). A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med, 35, 158–176.
- Kayir H, Goktalay G, Yildirim M, Uzbay TI. (2009). Clozapine inhibits development and expression of nicotine-induced locomotor sensitization in rats. Synapse, 63, 15–21.
- Krenn L. (2002). [Passion Flower (Passiflora incarnata L.)–a reliable herbal sedative]. Wien Med Wochenschr, 152, 404–406.
- Ksir C, Hakan RL, Kellar KJ. (1987). Chronic nicotine and locomotor activity: influences of exposure dose and test dose. Psychopharmacology (Berl), 92, 25–29.
- Li Z, DiFranza JR, Wellman RJ, Kulkarni P, King JA. (2008). Imaging brain activation in nicotine-sensitized rats. Brain Res, 1199, 91–99.
- Moeller DW, Sun LS. (2010). Chemical and radioactive carcinogens in cigarettes: Associated health impacts and responses of the tobacco industry, U.S. Congress, and federal regulatory agencies. Health Phys, 99, 674–679.
- Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M. (2008). Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: A double-blind, placebo-controlled study. Anesth Analg, 106, 1728–1732.
- Nassiri-Asl M, Shariati-Rad S, Zamansoltani F. (2007). Anticonvulsant effects of aerial parts of Passiflora incarnata extract in mice: Involvement of benzodiazepine and opioid receptors. BMC Complement Altern Med, 7, 26.
- Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O’Connell TN, Zandi KS, Miller S, Coe JW. (2006). Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos, 34, 121–130.
- Paterson NE, Balfour DJ, Markou A. (2007). Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci, 25, 3099–3108.
- Rennard SI, Daughton DM. (2000). Smoking cessation. Chest, 117, 360S–364S.
- Soulimani R, Younos C, Jarmouni S, Bousta D, Misslin R, Mortier F. (1997). Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. J Ethnopharmacol, 57, 11–20.
- Werneke U, Turner T, Priebe S. (2006). Complementary medicines in psychiatry: Review of effectiveness and safety. Br J Psychiatry, 188, 109–121.
- Zanoli P, Avallone R, Baraldi M. (2000). Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia, 71 Suppl 1, S117–S123.